You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. This newly revised compendium reviews the most current research and development on drug resistance while still providing the information in the accessible format of the first edition. The first volume, Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant o...
For many years, physicians and the public assumed that the discovery of new antimicrobial agents would outpace the ability of bacteria to mutate and develop drug resistance. Yet the development of new antibiotics has not kept up with bacterial evolution, especially since the late 1990’s. At that time a multitude of pharmaceutical companies abandoned antibiotic research because of strong economic disincentives. For example, it is challenging for these companies to recuperate the investment (typically in the hundreds of millions of dollars) made in developing a new antibiotic, which is typically prescribed for a few days, compared to drugs that treat chronic conditions like heart disease or ...
Together with Consulting Editor Dr. Helen Boucher, Drs. Watkins and Bonomo have put together an issue of Infectious Disease Clinics of North America that provides the most current information on antibiotic resistance. Top experts have contributed clinical review articles that address the types of resistance based on drug class as well as emerging therapies and the future of telemedicine in the management of infections. The following topics are covered in this issue: The changing role of the clinical microbiology laboratory in defining resistance in gram-negatives; Extended-spectrum β-lactamase-producing Enterobacteriaceae infections; Multidrug-resistant bacteria in the community; Resistance...
It is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; howev...
Antibiotics and antibiotic resistance have most commonly been viewed in the context of human use and effects. However, both have co-existed in nature for millennia. Recently the roles of antibiotics and antibiotic resistance genes have started to be discussed in terms of functions other than bacterial inhibition and protection. This special topic will focus on both the traditional role of antibiotics as warfare mechanisms and their alternative roles and uses within nature such as antibiotics as signals or communication mechanisms, antibiotic selection at low concentrations, the non-specific role of resistance mechanisms in nature: e.g. efflux pumps, evolution of antibiotic resistance and the role of persisters in natural antibiotic resistance.
Antibiotics represent one of the most successful forms of therapy in medicine. But the efficiency of antibiotics is compromised by the growing number of antibiotic-resistant pathogens. Antibiotic resistance, which is implicated in elevated morbidity and mortality rates as well as in the increased treatment costs, is considered to be one of the major global public health threats (www.who.int/drugresistance/en/) and the magnitude of the problem recently prompted a number of international and national bodies to take actions to protect the public (http://ec.europa.eu/dgs/health_consumer/docs/road-map-amr_en.pdf: http://www.who.int/drugresistance/amr_global_action_plan/en/; http://www.whitehouse....
This ? rst edition of Antimicrobial Drug Resistance grew out of a desire by the editors and authors to have a comprehensive resource of information on antimicrobial drug resistance that encompassed the current information available for bacteria, fungi, protozoa and viruses. We believe that this information will be of value to clinicians, epidemiologists, microbiologists, virologists, parasitologists, public health authorities, medical students and fellows in training. We have endeavored to provide this information in a style which would be accessible to the broad community of persons who are concerned with the impact of drug resistance in our cl- ics and across the broader global communities...
While some books present “ideal” ethnographic field methods, Inside Ethnography shares the realities of fieldwork in action. With a focus on strategies employed with populations at society’s margins, twenty-one contemporary ethnographers examine their cutting-edge work with honesty and introspection, drawing readers into the field to reveal the challenges they have faced. Representing disciplinary approaches from criminology, sociology, anthropology, public health, business, and social work, and designed explicitly for courses on ethnographic and qualitative methods, crime, deviance, drugs, and urban sociology, the authors portray an evolving methodology that adapts to the conditions of the field while tackling emerging controversies with perceptive sensitivity. Their judicious advice on how to avoid pitfalls and remedy missteps provides unusual insights for practitioners, academics, and undergraduate and graduate students.
According to the American Cancer Society, more than 1.6 million people will be diagnosed with cancer during this year. Outcomes have steadily risen over the last several decades with the advent of newer therapies. As outcomes have improved, more and more cancer patients are developing critical illness. In the not-too-distant past, patients with active malignancy were thought not appropriate for critical care services as decreased longevity related to the cancer suggested poor prognosis for intensive care utilization. More recently, evidence supports rapid activation of critical care services leading to improved outcomes in cancer patients. Moreover, just as sub-subspecialty critical care experience in trauma and neurosciences has proved beneficial, the emerging field of oncology critical care warrants specific attention.